0001193125-22-261828.txt : 20221013 0001193125-22-261828.hdr.sgml : 20221013 20221013070828 ACCESSION NUMBER: 0001193125-22-261828 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221013 FILED AS OF DATE: 20221013 DATE AS OF CHANGE: 20221013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VectivBio Holding AG CENTRAL INDEX KEY: 0001836379 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40316 FILM NUMBER: 221308084 BUSINESS ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 BUSINESS PHONE: 41 61 551 30 30 MAIL ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 6-K 1 d394749d6k.htm FORM 6-K FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of October 2022

Commission File Number 001-40316

 

 

VECTIVBIO HOLDING AG

(Exact name of registrant as specified in its charter)

 

 

Aeschenvorstadt 36

4051 Basel

Switzerland

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

Suspension of Sales and Downsize under At-The-Market Offering Program

On October 12, 2022, VectivBio Holding AG (the “Company”) delivered notice to SVB Securities LLC (“SVB Securities”) that it was suspending the prospectus (the “ATM Prospectus”) related to the sale of its ordinary shares with a nominal value of CHF 0.05 each (the “Ordinary Shares”) in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated as of May 4, 2022, between the Company and SVB Securities (the “Sales Agreement”) and reducing the amount of securities available for issuance under the ATM Prospectus and pursuant to the Sales Agreement to $40 million from $75 million.

The Company will not make any sales of its Ordinary Shares pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. The Sales Agreement remains in full force and effect. As of October 12, 2022, the Company has not issued and sold any Ordinary Shares under the ATM Prospectus.

A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company’s Registration Statement on Form F-3 (333-264653), which was originally filed with the Securities and Exchange Commission on May 4, 2022.

Incorporation by Reference

The Company hereby incorporates by reference the information contained in the body of this Report on Form 6-K into the Company’s registration statements on Form S-8 (File No. 333-255524) and Form F-3 (File No. 333-264653) (including any prospectuses forming a part of such registration statements) and deems it to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    VECTIVBIO HOLDING AG
October 13, 2022     By:  

/s/ Claudia D’Augusta

      Claudia D’Augusta
      Chief Financial Officer